DUTOPROL
LOE Approachinghydrochlorothiazide; metoprolol succinate
NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DUTOPROL (hydrochlorothiazide; metoprolol succinate) is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 2006.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUTOPROL is a fixed-dose combination oral tablet containing hydrochlorothiazide (a thiazide diuretic) and metoprolol succinate (a beta-blocker), approved in 2006 for hypertension management. The combination works through dual mechanisms: metoprolol reduces heart rate and cardiac output via beta-blockade, while hydrochlorothiazide increases sodium and chloride excretion to reduce blood volume and peripheral resistance. This synergistic approach addresses both sympathetic and fluid-volume components of hypertension.
LOE Approaching
Product is in LOE-approaching phase with competitive pressure at 30/100, signaling declining team investment and fewer open headcount opportunities.
Mechanism of Action
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Indications (1)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.